This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, X. Articles by Portale, A. A. Search for Related Content PubMed PubMed Citation Articles by Wang, X. Articles by Portale, A. A.

Novel Gene Mutations in Patients with 1-Hydroxylase Deficiency That Confer Partial Enzyme Activity in Vitro

Department of Pediatrics, University of California, San Francisco, California 94143

Address all correspondence and requests for reprints to: Anthony A. Portale, M.D., University of California, 533 Parnassus Avenue, Room U-585, Box 0748, San Francisco, California 94143-0748. E-mail: . aportale{at}peds.ucsf.edu

Abstract

The rate-limiting, hormonally regulated step in the biological activation of vitamin D is its 1-hydroxylation to 1,25-dihydroxyvitamin D [1,25-(OH)₂D] in the kidney, catalyzed by the mitochondrial cytochrome P450 enzyme, P450c1. We previously cloned the human P450c1 cDNA and gene, and identified 14 different mutations, including 7 missense, in 19 patients with 1-hydroxylase deficiency, also known as vitamin D-dependent rickets type 1. None of the missense mutations encoded a protein with detectable enzymatic activity in vitro. Although there is phenotypic variation among such patients, the molecular basis of this variation is unknown. We analyzed 6 additional patients with clinical and radiographic features of rickets; in 4 patients the laboratory abnormalities were typical of 1-hydroxylase deficiency, but in 2 they were unusually mild [mild hypocalcemia and normal serum 1,25-(OH)₂D concentration]. Direct sequencing revealed that all patients had P450c1 mutations on both alleles. Five new and 2 known mutations were identified. The new mutations included a 5-bp deletion with a 6-bp novel insertion causing a frameshift in exon 2, and a G to A change at +1 of intron 2; a minigene experiment proved that this intronic mutation prevented proper splicing. Three new missense mutations were found and tested by expressing the mutant cDNA in mouse Leydig MA-10 cells. The R389G mutant was totally inactive, but mutant L343F retained 2.3% of wild-type activity, and mutant E189G retained 22% of wild-type activity. The two mutations that confer partial enzyme activity in vitro were found in the 2 patents with mild laboratory abnormalities, suggesting that such mutations contribute to the phenotypic variation observed in patients with 1-hydroxylase deficiency.

This article has been cited by other articles:

				C. J. Kim, L. E. Kaplan, F. Perwad, N. Huang, A. Sharma, Y. Choi, W. L. Miller, and A. A. Portale Vitamin D 1{alpha}-Hydroxylase Gene Mutations in Patients with 1{alpha}-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3177 - 3182. [Abstract] [Full Text] [PDF]

				H. Chen, M. Hewison, B. Hu, and J. S. Adams Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: A cause of vitamin D resistance PNAS, May 13, 2003; 100(10): 6109 - 6114. [Abstract] [Full Text] [PDF]

				T. O. Carpenter Variable Degrees of 1-{alpha} Hydroxylase Activity--Fine Tuning the Rachitic Rheostat J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2421 - 2423. [Full Text] [PDF]